Clinical Trials · NCT00489918

Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

CompletedPhase 2Teriparatide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Zosano Pharma Corporation
Enrollment
165
Start date
Jun 2007
Locations
See registry
Primary endpoint
Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24
View Teriparatide compound reference